Drug Profile
RO 638455
Latest Information Update: 28 Nov 2006
Price :
$50
*
At a glance
- Originator Roche
- Class Antihypertensives
- Mechanism of Action Renin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 12 Jun 2001 No-Development-Reported for Hypertension in Switzerland (PO)
- 25 Sep 1997 Preclinical development for Hypertension in Switzerland (PO)